Top news of the week: 19.05.2020.

#Biotechnology #COVID19 #biology #farming #technology #food

Startups

On May 14, 2020
@BiotechWorld shared
J&J-backed CAR-T biotech Legend guns for $100M IPO but sees CRS death in early trial https://t.co/4e40uJIuaE https://t.co/UpLNx5nJTg
Open

J&J-backed CAR-T biotech Legend guns for $100M IPO but sees CRS death in early trial

J&J-backed CAR-T biotech Legend guns for $100M IPO but sees CRS death in early trial

Legend Biotech is hoping it can ride the biotech IPO wave and take in a cool $100 million for its cell therapy work.

On May 16, 2020
@Forbes shared
Meet the Harvard professor who became a billionaire thanks to coronavirus: https://t.co/excC5sVHd8 https://t.co/aqgUvaYWC7
Open

Exclusive: Meet The Harvard Professor Who Became A Billionaire Thanks To Coronavirus

Exclusive: Meet The Harvard Professor Who Became A Billionaire Thanks To Coronavirus

A decade ago, Timothy Springer made an investment on a fledgling biotech company. Now he talks about that bet and other investments.

On May 15, 2020
@matthewherper shared
RT @stephaniemlee: SCOOP: I obtained a whistleblower complaint about Stanford's COVID-19 study. Turns out JetBlue's founder, a critic of the economic shutdowns, helped fund it. And John Ioannidis and others allegedly ignored internal scientists' concerns about the test. https://t.co/dExNhZTVX0
Open

JetBlue’s Founder Helped Fund A Stanford Study That Said The Coronavirus Wasn’t That Deadly

JetBlue’s Founder Helped Fund A Stanford Study That Said The Coronavirus Wasn’t That Deadly

A Stanford whistleblower complaint alleges that the controversial John Ioannidis study failed to disclose important financial ties and ignored scientists’ concerns that their antibody test ...

On May 12, 2020
@BIOConvention shared
Ready to meet the next big thing in our industry? Check out our Start-Up Stadium finalists! These 30 companies are going to go far and do big things. https://t.co/oTNJm4i3gq https://t.co/ahLilcc6nH
Open

Start-Up Stadium

Start-Up Stadium

Start-Up Stadium was designed to provide start-up companies with the opportunity to engage key members of the investment community, venture philanthropy groups, strategic partners, and ...

On May 14, 2020
@Xconomy shared
Biotech “Mapmaker” Immunai Launches With $20M to Chart the Immune System - by @frankvinluan https://t.co/Eo3UEuGqBU $ADPT $MFST
Open

Biotech “Mapmaker” Immunai Launches With $20M to Chart the Immune System

Biotech “Mapmaker” Immunai Launches With $20M to Chart the Immune System

It may seem like an unlikely link but the body’s response to arthritis may hold answers for better cancer drugs, says Luis Voloch, chief technology

On May 17, 2020
@IAmBiotech shared
#Biotechnology is key to building more resilient #food and #farming systems. The #COVID19 crisis shows us the fragility of these systems and shines a bright light on the essential role of #biology and #technology in our lives. More: https://t.co/ABO3gucrC2
Open
On May 13, 2020
@rowe shared
New book alert: Celebrating Entrepreneurs by MIT Prof. Ed Roberts. Explores the back-stories of the multiple entire industries pioneered by MIT entrepreneurs. Written by a rare individual who saw most of it happen first-hand, and helped guide much of it. https://t.co/hNxTX9pKZa
Open

Book Description

Book Description

Then, with in-depth coverage of the founders and companies that pioneered four industries—biotechnology, the Internet, from CAD-CAM to robotics, and modern finance—plus many other …

On May 14, 2020
@Xconomy shared
Boehringer Ingelheim Acquires Northern Biologics’ Preclinical Pipeline - by @sarahdc https://t.co/lWouYRRf6Z
Open

Boehringer Ingelheim Acquires Northern Biologics’ Preclinical Pipeline

Boehringer Ingelheim Acquires Northern Biologics’ Preclinical Pipeline

Two preclinical programs developed by Canadian biotech Northern Biologics have been acquired by privately held German company Boehringer Ingelheim, which